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Nowadays it is well known that patients with established 
rheumatoid arthritis (RA) suﬀ   er from an increased 
cardio  vascular risk in comparison with the general popu-
lation, and both traditional cardiovascular risk factors as 
well as the underlying chronic inﬂ  ammatory  process 
contribute to this excess cardiovascular risk. Little is 
known, however, about the cardiovascular risk in early 
RA patients – hence the recent article by Södergren and 
colleagues could be an important contribution to the 
ﬁ  eld [1].
Th   e increased cardiovascular risk in RA is mainly due 
to atherosclerotic events. Until recently atherosclerosis 
was considered an accumulation of lipoproteins within 
the arterial wall. During the past decade, however, 
athero  sclerosis has been recognized as a chronic 
inﬂ  ammatory process in the artery. Th  e  ﬁ  rst step in the 
process is endothelial dysfunction caused by traditional 
cardio  vascular risk factors such as smoking. Th  e 
endothelium becomes more permeable – to lipids, for 
example – and becomes procoagulant instead of anti-
coagulant. Th  e  inﬂ  ammatory response further results in 
an entry of inﬂ  ammatory cells and muscle cells. Foam 
cells are formed and result in fatty streaks. Th  is lesion 
progresses and a ﬁ   brous cap is formed, consisting of 
smooth muscle cells and a collagen matrix that separates 
this atherosclerotic plaque from the arterial lumen. 
Ultimately, the plaque may rupture and the subsequent 
thrombosis causes a myocardial infarction.
In the study by Södergren and colleagues, the carotid 
intima media thickness (cIMT) (a marker of preclinical 
atherosclerosis) and ﬂ   ow-mediated dilatation of the 
brachial artery (a marker of endothelial dysfunction) 
were assessed in 79 early RA patients and in 44 age-
matched and sex-matched controls. In a subgroup of 27 
RA patients (and controls), the assessments were 
repeated after 18  months. Carotid plaques, another 
feature of preclinical athero  sclerosis that can be assessed 
during cIMT measurement, were not reported. Th  e  ﬂ  ow-
mediated dilatation and the cIMT at baseline were not 
signiﬁ  cantly  diﬀ   erent between the two groups. Th  is 
observation is remarkable particu  larly for the cIMT, as 
RA patients had signiﬁ  cantly more cardiovascular risk 
factors (hypertension, smoking and dyslipidemia) – 
important determinants of the cIMT [2] – than the 
controls, and one would expect at least a tendency for an 
increased cIMT in RA patients, whereas an opposite 
trend was seen. Moreover, these results contradict 
ﬁ   ndings from other studies that indicate an increased 
rate of cardiovascular events as well as cardiovascular 
risk factors before the clinical onset of RA.
Th  e cIMT thickness in both groups was, as expected, 
associated with the traditional cardiovascular risk factors, 
and no relationship with disease activity markers was 
found in the RA group. Th   is latter ﬁ  nding is in line with 
the results of our recent meta-analysis of cIMT in 
established RA patients, where also no relationship with 
disease activity could be demonstrated [3]. Perhaps using 
a cumulative disease activity marker (for example, 
number of erosions) would have been more appropriate 
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duration/severity and cardiovascular risk. Moreover, this 
meta-analysis revealed a cIMT diﬀ   erence of 0.09  mm 
between RA patients and controls, indicating an approxi-
mately 15% increased cardiovascular risk [4]. Th  is  value 
is far less than expected in view of the 50 to 100% 
increased cardiovascular risk demonstrated in early RA 
and established RA patients [5,6]. Th  e majority of the 
cardiovascular events are caused by plaque ruptures, 
which must imply that plaques rupture earlier in an 
inﬂ   ammatory situation than in a non-inﬂ  ammatory 
situation [7].
Th   e observed increase in cIMT for RA patients in the 
study by Södergren and colleagues was 0.05 mm in 
18 months, and was signiﬁ  cantly larger than that in the 
control group. Th   is value ﬁ   ts within the increase 
observed in a much larger investi  gation in the general 
population [8], however, so it is tempting to speculate 
that this normal cIMT progression in RA patients was 
due to eﬀ   ective antirheumatic treatment, nowadays 
aimed at remission, even though prospective data about 
disease activity were not provided.
Although there remain some methodological issues, 
the study by Södergren and colleagues clearly under-
scores two pivotal aspects about the cardiovascular risk 
in RA: an increased prevalence of cardiovascular risk 
factors in RA, and that eﬀ  ective antirheumatic treatment 
probably decreases the cardiovascular risk in RA. Th  eir 
study therefore supports the recently published European 
League Against Rheumatism recommendations for cardio-
vascular risk management in inﬂ  ammatory  arthritis 
patients, which advocate that cardiovascular risk manage-
ment should be aimed at disease activity suppres  sion as 
well as at cardiovascular risk factor screening and treat-
ment [9].
As the present ﬁ  ndings are in contradiction with the 
existing literature, larger prospective, controlled investi-
gations with a rigorous methodological design are 
necessary. Another challenging topic for future studies is 
how to identify the patients with a high risk for plaque 
rupture. Such studies may hopefully become redundant 
when it is demonstrated that eﬀ  ective  antirheumatic 
therapy, aimed at disease remission, normalizes the 
change of plaque rupture.
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